Holen Sie sich die Stockscreener-App
9.61
4.68%
0.43
Satellos Bioscience Inc Aktie (MSLE) Neueste Nachrichten
Satellos Bioscience is facing clinical execution risks—can it regain investor confidence and turn sentiment around? - kalkine.ca
Satellos assigns INN forazapadin to DMD drug candidate By Investing.com - Investing.com Canada
A muscle disease treatment candidate gets a new global name: forazapadin - Stock Titan
Satellos Bioscience Inc. (NASDAQ:MSLE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Why Did Satellos Bioscience (TSX:MSCL) Surge 7.43% on 31 August 2026? - kalkine.ca
Why Satellos Bioscience Inc. stock surged yesterday - Wealth Awesome
Satellos Bioscience to Showcase DMD Drug Program at September Investor Conferences - TipRanks
Satellos cash runway through 2027, Phase 2 DMD | MSLE SEC FilingForm 6-K - Stock Titan
Satellos to Participate in Upcoming Investor Conferences - Stock Titan
Satellos Bioscience (TSX:MSCL) Rises 7.43% as Duchenne Clinical Progress and Upcoming Data Catalysts Lift Investor Optimism - kalkine.ca
Satellos Bioscience Stock Falls 7.42% as Clinical-Stage Risk and Development Uncertainty Pressure Sentiment - kalkine.ca
Satellos Bioscience Inc. (TSX:MSCL) Falls 7.42% as Biotech Volatility and Clinical Development Risks Pressure Investor Confidence - kalkine.ca
LifeSci Capital Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Satellos Bioscience (MSLE) Slides Nearly 10% in High-Volume Biotech SelloffCalendar Spread Trade - vinanet.vn
Empery Asset Management LP Sells 123,000 Shares of Satellos Bioscience Inc. $MSLE - MarketBeat
LifeSci Capital Initiates Satellos Bioscience(MSLE.US) With Buy Rating, Announces Target Price $22 - Moomoo
Satellos Bioscience Stock Under Pressure as Biotech Volatility Raises Correction Risk - kalkine.ca
Satellos (MSLE) Stock: Ends Higher by 0.59% at $10.15 on the Day; Current Setup: the Session Ends Within the Reported Technical Boundaries in the Latest ReadingMonthly Profile - vinanet.vn
DMD Biotech Delivers Early Muscle Data as SAT-3247 Advances - Streetwise Reports
Why Satellos Bioscience Inc. stock is gaining today - wealthawesome.com
Satellos Bioscience (MSLE) Institutional Ownership 2026 - MarketBeat
Satellos Bioscience Stock Drops 3.39% as Investors Weigh Duchenne Muscular Dystrophy Therapy, Clinical Development and Biotech Risk - kalkine.ca
Why Satellos Bioscience Inc. stock fell yesterday - Wealth Awesome
HC Wainwright Reaffirms Buy Rating for Satellos Bioscience (NASDAQ:MSLE) - MarketBeat
H.C. Wainwright Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Satellos Bioscience Inc. MSCL Earnings Miss Estimates by 37.0% - Wealth Awesome
Satellos TRAILHEAD Data Suggests Muscle Regeneration as Company Cash Reaches US$61.8M - Streetwise Reports
Satellos Bioscience Sets Up US$50 Million U.S. At-the-Market Share Sales Facility - TipRanks
Satellos Bioscience (MSLE) enters $50M at-the-market share deal - Stock Titan
Satellos Bioscience Inc. Stock 12‑Month Price Target Cut to $21.78, Implies 122% Upside - TradingView
Why Satellos Bioscience Inc. stock is sliding today - Wealth Awesome
Satellos Bioscience Inc. Stock 12‑Month Price Target Cut to $21.92, Implies 123% Upside - TradingView
Oppenheimer Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Satellos Bioscience Inc.Common Stock (MSLE) Stock Price, News, Quote & History - FinancialContent
Satellos reports improved muscle composition in TRAILHEAD study - scanx.trade
Satellos Bioscience: Q2 Earnings Snapshot - aol.com
Satellos Bioscience Posts Larger Q2 2026 Loss on Higher R&D but Doubles Equity Base - TipRanks
Satellos Q2 loss widens to $11.7M, EPS misses estimates - scanx.trade
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress - The Manila Times
Satellos Bioscience (NASDAQ: MSLE) ramps Duchenne R&D and strengthens cash - Stock Titan
Satellos Bioscience Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Satellos Bioscience Files For Mixed Shelf Of Up To $300 Million - TradingView
Satellos Bioscience (MSLE) sets up US$300M shelf to fund Duchenne drug - Stock Titan
Satellos Bioscience (MSLE) Holds Ground Near $10.01 as Key Support Level Comes into FocusInitial Balance - dars.gov.et
Satellos Bioscience Inc. (TSX:MSCL) Stock Declines as Biotech Risks and Funding Concerns Pressure Sentiment - kalkine.ca
Satellos Bioscience (TSX:MSCL): Can This Toronto Biotech Actually Regrow Muscle in Duchenne Patients? - kalkine.ca
Satellos Bioscience Stock Climbs as Duchenne Therapy Data Strengthen Bullish Momentum: Can TSX:MSCL Extend Its Recovery? - kalkine.ca
Satellos Wins FDA Fast Track for SAT-3247 as Its Duchenne Programme Enters a Catalyst-Rich Second Half - kalkine.ca
Why Satellos Bioscience Inc. stock is skyrocketing today - Wealth Awesome
Satellos Bioscience Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Satellos Bioscience Inc. (TSX:MSCL) Faces Crucial Smallcap Tests - Kalkine Media
Satellos Bioscience Inc. (TSX:MSCL) Faces Renewed Selling Pressure as Biotech Volatility Weighs on Investor Confidence - kalkine.ca
MSLE|Satellos Bioscience Ord Shs|Price:8.970|Chg%:-0.110 - TradingKey
Satellos Bioscience Ord Shs (MSLE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Satellos Bioscience Ord Shs (MSLE) Institutional Confidence - TradingKey
Satellos Bioscience Inc Revenue Breakdown – LSX:A4211W - TradingView
What's Going On With Satellos Bioscience Inc. Stock Wednesday? - Wealth Awesome
0.69%
3.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):